{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-134447","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.094805+00:00","generated_at":"2026-05-19T23:57:11.953723+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Stoke Therapeutics initiates Phase 3 EMPEROR study of zorevunersen; first US sites in May 2025","bullets":["Initiated Phase 3 EMPEROR study of zorevunersen; first U.S. sites activated in May 2025.","Updated corporate presentation posted to website on June 4, 2025, for Jefferies Global Healthcare Conference.","No other material financial or operational updates disclosed beyond the study initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-134447","json":"https://secwatch.observer/filing/0001193125-25-134447.json","markdown":"https://secwatch.observer/filing/0001193125-25-134447.md","text":"https://secwatch.observer/filing/0001193125-25-134447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525134447/0001193125-25-134447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525134447/d36270d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T23:57:11.953723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}